This review summarizes the pathogenesis and current management strategies for NAFLD and NASH, emphasizing lifestyle modifications and pharmacologic control of metabolic risk factors.
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has also been strongly associated with type II diabetes and cardiovascular diseases. This study was a multipurposed review, which included discussion of recent studies investigating the cellular and genetic basis of these diseases, the pathogenesis of NAFLD and the current treatment and management of nonalcoholic steatohepatitis. Currently, maintaining a healthy weight through dietary changes and exercise, the use of insulin-modulating pharmacologic agents for diabetes control and the use of lipid-lowering, anti-oxidants have been the most widely recommended treatments. Inclusion of pathogenic mechanisms in treatment design will allow future therapies to target-specific pathways involved in NAFLD pathogenesis.
No takes yet. Share an insight, caveat, or question.
Elsheikh et al. (2013) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Current management (dietary changes, exercise, pharmacologic agents) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: